Using AI to predict who will respond to placebo

April 16, 2023

Placebo response is a bane of clinical trials but it can be very helpful in practice. A team of American and Canadian researchers used AI to help identify predictors of the placebo response. The results were recently published in Pain, under the title, Predicting placebo analgesia in patients with chronic pain using natural language processing: a preliminary validation study.

Since they used AI for their study, I thought it would be fitting to use ChatGPT to edit their abstract for the lay public.

Patients with chronic pain often experience significant pain relief from placebos (inert pills), and this effect can last for days or even weeks. However, it’s still unclear whether we can reliably predict who will respond to placebo and how to do so. Previous research has shown that people who respond well to placebos tend to talk about their pain and their life in a certain way. In this study, the researchers looked at whether these language patterns can predict who will respond to a placebo before they even receive the treatment, and whether we can distinguish between people who will respond to a placebo versus a real drug.

To do this, they analyzed language patterns from patients with chronic back pain who received a placebo in one study and used this information to build a language model that could predict who would respond to a placebo in a separate study. They found that this language model was able to predict, before treatment, which patients would respond well to a placebo in the second study. These patients reported an average of 30% pain relief from the placebo, while those predicted to be non-responders only experienced a 3% reduction in pain. However, the model was not able to predict who would respond to a real pain medication or who would recover without treatment, suggesting that it specifically predicts response to placebos.

Overall, this study suggests that we may be able to use language patterns to predict who will respond to placebos, which could help researchers design better clinical trials and improve patient care.

Written by
Alexander Mauskop, MD
Continue reading
May 21, 2026
Research
Your Brain Has Many Pathways, And TMS Can Now Use Them
A groundbreaking University of Iowa study shows that personalized fMRI-guided TMS can now reach and modulate the deep hippocampus — the brain’s command center for memory, emotion, and migraine — without surgery or heavy medications. By mapping each patient’s unique neural pathways, TMS delivers precise stimulation to surface “control points” that influence deep brain structures. Generic approaches barely work, but individualized targeting produces clear, measurable changes. At our headache clinic, we combine TMS and fMRI to offer this advanced, personalized treatment for migraines, depression, PTSD, anxiety, and more.
Read article
May 10, 2026
Research
Elismetrep: A Promising New Experimental Migraine Treatment
Elismetrep is a promising experimental migraine medication that targets the TRPM8 pathway rather than serotonin or CGRP. Early clinical trials suggest it may offer a new option for patients who do not respond well to current treatments.
Read article
May 6, 2026
Alternative Therapies
New Research on Brain Excitability and TMS Treatment for Migraine
New research shows how the brain dynamically regulates excitability in real time—and why this matters for transcranial magnetic stimulation (TMS) as a treatment for migraine.
Read article
Insights from Dr. Alexander Mauskop on headaches and migraines
Subscribe to the Blog.
Subscribe
Subscribe